血清AFP、GP73和GPC3联合检测在原发性肝癌诊断中的应用

doi:10.3969/j.issn.1673-8640.2014.09.003

摘要/Abstract

摘要：

目的探讨甲胎蛋白(AFP)、高尔基体蛋白73(GP73)、磷脂酰肌醇蛋白聚糖3(GPC3)联合检测在原发性肝癌(PHC)诊断中的临床应用价值。方法采用酶联免疫吸附试验(ELISA)检测148例PHC患者、73例肝硬化(LC)患者、57例慢性乙型肝炎(CHB)患者及85名健康人(正常对照组)血清GP73、GPC3含量,同时采用免疫化学发光法检测血清AFP含量,并对检测结果进行比较。结果 PHC组GP73、GPC3、AFP血清水平分别为346.9±208.7、143.1±66.9和(690.3±402.5)μg /L,与LC组、CHB组和正常对照组血清水平比较差异具有统计学意义(P均<0.01);血清AFP、GP73、GPC3联合检测诊断PHC的敏感性为95.9%,准确性为89.2%。结论血清AFP、GP73、GPC3联合应用能弥补单项肿瘤标志物临床应用的不足,对提高PHC的阳性检出率及鉴别诊断具有重要的临床意义。

关键词: 甲胎蛋白, 高尔基体蛋白73, 磷脂酰肌醇蛋白聚糖3, 联合检测, 原发性肝癌

Abstract:

Objective To investigate the application significance of the combination detection of alpha-fetoprotein (AFP), Golgi protein 73(GP73) and glypican 3(GPC3) on the diagnosis of primary hepatic carcinoma (PHC). Methods Enzyme-linked immunosorbent assay (ELISA) was used to detect the serum levels of GP73 and GPC3 in 148 patients with PHC, 73 patients with liver cirrhosis (LC), 57 patients with chronic hepatitis B (CHB) and 85 healthy subjects(healthy control group). Serum AFP was detected by chemiluminescence immunoassay. The levels of GP73 and GPC3 were compared with that of AFP. Results Serum levels of GP73, GPC3 and AFP in PHC group were 346.9±208.7, 143.1±66.9 and (690.3±402.5) μg/L, which were significant statistically compared with those inLC, CHB and healthy control groups (P<0.01). In the combination detection, the sensitivity was 95.9%, and the accuracy was 89.2%. Conclusions The combination detection of serum AFP, GP73 and GPC3 could cover the shortage of individual detections, increase the diagnosis rate of PHC and differentiate PHC with clinical significance.

Key words: Alpha-fetoprotein, Golgi protein 73, Glypican 3, Combination detection, Primary hepatic carcinoma

中图分类号:

R446.62

范公忍,王伟芳,韩聚强,姜胜莹,曹建彪. 血清AFP、GP73和GPC3联合检测在原发性肝癌诊断中的应用[J]. 检验医学, 2014, 29(9): 884-888.

FAN Gongren, WANG Weifang, HAN Juqiang, JIANG Shengying, CAO Jianbiao. Application of the combination detection of serum AFP, GP73 and GPC3 on the diagnosis of primary hepatic carcinoma[J]. , 2014, 29(9): 884-888.

参考文献

[1] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update [J]. Hepatology,2011,53(3):1020-1022.
[2] 武永乐,李冰,刘晖, 等. GPC3对AFP阴性乙型肝炎病毒相关肝细胞癌的诊断价值[J].北京医学,2013,35(6):416-419.
[3] 陈洁,姚敏,姚登福.磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗[J]. 临床肝胆病杂志,2013,29(1):77-80.
[4] 郑联坵,魏开鹏,潘兴南,等. 血清高尔体蛋白73诊断肝细胞癌价值探讨[J].实用肝脏病杂志,2013,18(5):407-410.
[5] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志,2011,27(11):1141-1159.
[6] 翁彭剑,高园生,鲁姣英,等. 检测血清GP73对PHC诊断价值的探讨[J].中国卫生检验杂志,2011,21(8):1971-1973.
[7] 朱凡,沈世强,柯章明.中晚期肝癌患者综合治疗的临床观察[J].中国肿瘤临床与康复,2013,20(6):569-571.
[8] Ba MC,Long H, Tang YQ, et al. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review[J]. Int J Clin Exp Pathol,2012,5(9):874-881.
[9] Marrero JA, Romano PR, Nikolaeva O,et al. GP73, a resident Golgi glycoprotion, is a novel serum marker for hepatocelluar carcinoma[J]. J Hepatol,2005,43(6):1007-1012.
[10] Kladney RD, Bulla GA,Guo L,et al. GP73, a novel Golgi-localized protein upregulated by viral infection[J]. Gene,2000,249(1-2):53-65.
[11] Kladney RD,Cui X, Bulla GA, et al. Expression of GP73, a resident Golgi membrame protein,in viral and nonviral liver disease[J]. Hepatology,2002,35(6):1431-1440.
[12] Mao YL, Yang HY, Xu HF, et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma:a primary study[J]. Zhonghua Yi Xue Za Zhi,2008,88(14):948-951.
[13] Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycoprotein, is sensibility and speecificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population[J]. Med Oncol,2010,27(2):339-345.
[14] 李继荣. 血清高尔基体蛋白73对原发性肝癌的早期诊断价值探讨[J].检验医学,2013,28(2):166-167.
[15] 杨颖,肖蕾,毛睿,等.高尔基体糖蛋白73的表达特征及其对肝癌与肝硬化的鉴别诊断价值[J].中华肝脏病杂志,2012,20(12):920-924.
[16] Tian L, Wang Y, Xu D, et al. Serological AFP/Golgi protein 73 could be a new diagnostic parameter of hepatic diseases[J]. Int J Cancer,2011,129(8): 1923-1931.
[17] Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy [J]. Eur J Cancer, 2011, 47(3):333-338.
[18] Liu S, Li Y, Chen W, Zheng P, et al. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells[J]. Biochem Biophys Res Commun,2012,419(4):656-661.
[19] Nobuoka D, Motomura Y, Shirakawa H, et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes[J]. Int J Oncol, 2012, 40(1):63-70.
[20] 江枫,肖明兵, 倪润洲,等.血清glypican 3 ELISA检测法的建立及初步应用[J].临床检验杂志,2011,29(4):244-246.
[21] Yao M, Yao DF, Bian YZ, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma[J]. Hepatobiliary Pancreat Dis Int,2011,10(3):289-294.
[22] Wang Y, Yang H, Xu H, et al. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-fetoprotein for hepatocelluar carcinoma diagnosis[J]. J Gastroenterol Hepatol, 2014,29(3): 597-602.
[23] 谢明水,刘杨,陈丹丹,等. AFP-L3、GP73、GPC3联合检测在原发性肝癌诊断中的应用价值[J]. 国际检验医学杂志,2004,26(5):519-520.
[24] Yamamoto K, Imamura H, Matsuyama Y, et al. AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC[J]. J Gastroenterol, 2010, 45(12):1272-1282.